Japan Agency for Medical Research and Development (AMED)

日本医療研究開発機構

Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…

Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…

Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…

Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…